José Luis Lanciego Pérez-rekin lankidetzan egindako argitalpenak (6)

2019

  1. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease

    Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910

2017

  1. Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors

    Frontiers in Pharmacology, Vol. 8, Núm. OCT

2016

  1. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

  2. Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay

    Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 3, pp. 580-587

2014

  1. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

2013

  1. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD

    Neuropharmacology, Vol. 64, pp. 114-123